Clinton Ray and Guy Morgan to Join Perella Weinberg Partners
Perella Weinberg Partners (“PWP”) announced today that Clinton Ray and Guy Morgan will join the Firm’s Advisory business in June 2019, based in London. Mr. Ray will join PWP as a Partner, and Mr. Morgan will join as a Managing Director. Mr. Ray and Mr. Morgan bring significant experience in restructuring, debt advisory and liability management. They will lead the expansion of PWP’s financial restructuring capabilities in Europe, working closely with the Firm’s European industry sector teams and US restructuring and capital structure advisory team to provide an expanded service offering to clients.
Dietrich Becker, Partner and Head of European Advisory at PWP, commented, “We are very excited to welcome Clinton and Guy to PWP as we continue to add to the breadth of our advisory offering in Europe. Their additions build on the success we have achieved with a highly integrated approach between sector and restructuring bankers in the US. Our new colleagues’ expertise will complement our focused sector teams, further enhancing our ability to offer clients the deep strategic advice they need when making their most critical business decisions.”
Bruce Mendelsohn, Partner and Head of Restructuring at PWP, commented, “Today’s announcement is an important and natural extension of our restructuring and capital structure advisory franchise. We have developed a highly synergistic approach to delivering these capabilities to our clients in close cooperation with our sector teams, and we look forward to extending our reach in the European market with the addition of Clinton and Guy.”
Mr. Ray and Mr. Morgan join PWP from Goldman Sachs. Mr. Ray served as a Managing Director and led the bank’s EMEA restructuring franchise for three years, advising on many of the largest European restructurings in recent years. Previously, he served as a Managing Director on Morgan Stanley’s restructuring team from 2007 to 2016, and as a Vice President at JP Morgan from 2004 to 2007. Mr. Ray began his professional career in 2001 at Clifford Chance LLP.
Mr. Morgan has served as a Managing Director and Head of Goldman Sachs’ Liability Management Group in EMEA since 2011. Previously, he spent 11 years at Deutsche Bank, including eight years as a Director in the Liability Management Group.
About Perella Weinberg Partners
Perella Weinberg Partners is a leading global independent advisory firm, providing strategic and financial advice to a broad client base, including corporations, institutions and governments. The firm advises clients across a range of the most active industry sectors and international markets. With more than 500 employees, Perella Weinberg Partners maintains offices in New York, Houston, London, Calgary, Chicago, Denver, Dubai, Los Angeles, Paris, and San Francisco. For more information on Perella Weinberg Partners, please visit: http://www.pwpartners.com.
Perella Weinberg Partners Media:
Perella Weinberg Partners
Margaret Popper/Robin Weinberg
Sard Verbinnen & Co
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetMedia Group takes over the management of financial platform Investing.com's European advertising space23.7.2019 08:07:00 CEST | Press release
NetMedia Group, media B2B leader in Europe in the world of business information, and Investing.com, second largest financial services and information platform in Europe, are to form a partnership, with NetMedia Group handling the sales of advertising space for Investing.com. With average traffic of over 21 million unique users totaling over 175 million sessions in 31 countries, Investing.com is one of the top three global financial websites and has the most downloaded financial management app. For Investing.com, the aim of the new partnership is to maximize digital advertising revenue through the NetMedia Group's European teams. NetMedia Group's goal is to expand its advertising services by offering a new vertical market for finance, in order to boost the range of services it has available to decision-makers for upper socio-professional target groups. About NetMedia Group: NetMedia Group is a B2B media group located in five countries across Europe; it employs nearly 150 staff members a
Frost & Sullivan Names Luminati the 2019 Global Market Leader in the Enterprise IP Proxy Networks Market23.7.2019 08:00:00 CEST | Press release
Luminati, the Israeli company that allows businesses to experience the web through the eyes of individual consumers throughout the world, today announced it has received a Market Leadership Award in the first independent analysis of the sector. Luminati’s enterprise IP proxy network (IPPN) services for global retailers, brand owners and advertising networks feature strongly in the report by analyst firm Frost & Sullivan. The report outlines a relatively new, but rapidly growing market and recognizes Luminati’s leading position in the provision of solutions that are increasingly important for businesses to remain competitive and compliant in the digital landscape. [S1] “The market for enterprise IP proxy network solutions is in its early growth stages, basically being invented by Luminati only a few years ago. With the more specialized targeting of customers by demographics and location, companies are finding it more difficult than ever to do competitive analysis and verify advertising,
LifeSpan BioSciences Releases Best-In-Class PathPlus™ Top Performing Immunohistochemistry Antibodies for Cancer Targets23.7.2019 08:00:00 CEST | Press release
LifeSpan BioSciences, Inc. (LSBio™), the industry leader in molecular pathology, today announced the first release of its PathPlus™ series of antibodies. These 565 antibodies were selected from among thousands tested and identified to be the best performing reagents for immunohistochemical detection of 200 high-value cancer targets in formalin-fixed paraffin-embedded human tissues. Antibody validation has become an industry roadblock as thousands of antibodies have become available to customers who face difficult choices in determining which antibodies are the best performers for each application, including immunohistochemistry, flow cytometry, ELISA, Western blot, or immunofluorescence. Antibodies that perform well in one assay, such as IHC, may not be the most specific reagent for another assay, such as flow cytometry. “Identifying the optimal reagents to use in their experiments is a pain point for researchers,” said LSBio CEO Heather Holemon. “There is a tremendous need to identify
IDEMIA Will Present Its H1 2019 Financial Results to Investors on July 30, 201923.7.2019 07:00:00 CEST | Press release
IDEMIA, the world leader in Augmented Identity, today announced that it will present its H1 2019 financial results to investors on Tuesday July 30, 2019. Yann Delabrière (CEO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 3:30 pm CET (2:30 pm London Time / 9:30 am New York Time). For more information, please refer to our website: https://investors.idemia.com/ About IDEMIA IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whet
Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible Applications23.7.2019 06:30:00 CEST | Press release
Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the
iBASIS Accelerates Growth With JC Geha as Chief Operating Officer23.7.2019 06:00:00 CEST | Press release
iBASIS, provider of communications solutions for operators and digital players worldwide, today announced the appointment of JC Geha as its COO. He will take his new post effective August 1, and be based at iBASIS’ headquarters in Lexington, Massachusetts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005757/en/ JC Geha (Photo: Business Wire) Formerly Senior Vice President, Head of International Technology and Services for Deutsche Telekom, and of Managed Services for Ericsson, Geha brings to iBASIS an impressive track record of profitable growth, technology and digital transformation expertise. His expertise spans 25 years of deep global industry relationships across the United States, Europe, Middle East, and Africa. Geha will lead iBASIS’ global operations, engineering, IT, and product development. He will report to iBASIS’ CEO and founder of the Group Tofane Global, Alexandre Pébereau, with the responsibility of g